Processa Pharmaceuticals-Aktie 52-Wochen-Tief $1.18 Von Investing.com

Processa Pharmaceuticals Inc. (PCSA) traded for $1.18 worth $52. The new Tiefststand has had a dramatic impact for biopharmaceutical products, which is a very good thing for me. Anleger must have an active company with a share of 82.11%. He dies after the Medical Treatment Phase of Improving Medical Treatment for Patients. 52-Wochen-Tief is an important indicator for market and investment transactions for Current Volatilität and pessimistic investment incentives.

Actively operating Processa Pharmaceuticals is a company that has been given a good clinical trial and unternehmenstruktur in Fortschritte. HC Wainwright has stopped a huge Kaufempfehlung festival with 12 Monat Courses from $8.00 to $6.00. Following Finance Processes for Two Quarters, a Nettoverlust of $1.01 died according to the Act. HC Wainwright made some predictions as a result of Nettoverlust.

NGC-Iri, a new clinical research process, acquired Wirkstoffkandidaten NGC-Iri for the best Concentration of the Molecule SN-38 worldwide. In the United States, the FDA has issued a New Drug (IND) for Phase-2 Study of Next-Generation Capecitabine (NGC-Cap) for Patients and Metastatic Metastases t.

Zusätzlich went into New Financing with Ernennung von Russell L. and went into a new Financing with Nachfolger alongside Ruhe and James Stanker. Schließlich headed Aktionäre wichtige Vorschläge genehmigt, Wahl von sechs Direktoren und die Innderung und Neufassung des Omnibus Incentive Plans 2019 des Unternehmens. These days, Processa Pharmaceuticals has a broader scope to operate in the Pharmaceutical Industry.

InvestingPro Insights

Processa Pharmaceuticals Inc. (PCSA) works with 52-Wochen-Tief together with Finance in Context and Erkenntnisse von InvestingPro. The new data covers PCSA’s capital market valuation of $4.01M, an amount that was valid more broadly. After 0.69 days on Buchwert’s top brand, this was a good thing in some monetary or financial sense.

PCSA’s investment Pro-Tipps such as “schnell Bargeld verrennt” and “under schwachen Bruttogewinnmargen leidet” were a stimulus to the latest active activity. Faktoren can have a wider range of investments with 52-Wochen-Tief. Darüber generated a “monetary gain of no profit” with a $10.53M operation for Monate in the 2024 quarter.

Herausforderungen weisen InvestingPro-Tipps und PCSA “mehr Bargeld als Schulden in seiner Bilanz halt” und “liquid Mittel die kurzfristigen Verpflichtungen übersteigen”, it was something with real financial flexibility n Schwierigkeiten verschaffen könnte. Für Investoren, die eine umfassendere Analysis such a, bietet InvestmentPro 5 Some tips on financial support and the use of PCSA.

Diese Übersetzung wurde mithilfe künstlicher Intelligenz erstellt. Learn more about the required information.